AstronauTx has received $1.2 million in research funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and Parkinson’s UK to explore whether improving restorative sleep could help slow the progression of Parkinson’s disease. The MJFF-funded project will investigate whether novel compounds developed by AstronauTx…
News
The U.S. Food and Drug Administration (FDA) has approved tavapadon — an oral drug aimed at maintaining consistent control of motor symptoms — as a new treatment for adults with Parkinson’s disease. The therapy’s developer, AbbVie, will market the once-daily med, taken as tablets, under the brand…
A rehabilitation program called PD-CoRE was shown to help adults with Parkinson’s disease improve their cognitive function and lessen symptoms of depression in a recent study. The program uses group sessions to teach practical problem-solving strategies, giving participants tools to manage the daily cognitive challenges that often accompany the neurodegenerative…
ACI-7104, AC Immune’s experimental vaccine for early Parkinson’s disease, was generally safe and triggered an immune response against aggregated alpha-synuclein, according to results from the first part of a Phase 2 trial. The findings from the VacSYn study (NCT06015841) included 34 participants, 25 who received ACI-7104 and…
Both aquatic Tai Chi and virtual reality (VR) training improved walking, balance, mobility, and gait symmetry in people with Parkinson’s disease. However, VR training led to greater improvements in several measures and maintained some of these benefits three months after training ended, a small clinical trial found. The study…
A $2.5 billion fundraising campaign launched by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to accelerate the development of new treatments and ultimately find a cure for Parkinson’s disease has reached the halfway mark, and the nonprofit is plugging for new donations. The multiyear campaign —…
A short, personalized intervention teaching people with Parkinson’s disease ways to manage anxiety that can trigger or worsen freezing of gait (FOG) — a common symptom in which individuals can not move their feet forward — did not significantly cut the number of such episodes when compared with no…
In a deal that could be worth more than $300 million, a Korean biotech has acquired exclusive global rights to develop and commercialize 1ST Biotherapeutics‘ 1ST-104, an oral treatment candidate targeting the causes of Parkinson’s disease. SK Biopharmaceuticals will bring its “clinical development and commercialization expertise” to the…
Demographics, social experiences, mental health, and sexual well-being are among factors playing significant roles in shaping health-related quality of life for people with Parkinson’s disease, a study from Ethiopia showed. “The age of participants, sex, coping [strategies], social support, [Parkinson’s]-related stigma, depression, sexual dysfunction and health satisfaction were independent…
A Parkinson’s disease therapy delivered through a wearable device eased motor function in some patients with advanced Parkinson’s, according to preliminary observations from an ongoing Phase 1b trial. An independent safety monitoring committee recommended that the trial of SER-252, Serina Therapeutics’ long-acting form of apomorphine, advance to a…
Recent Posts
- Stem cell therapy improves motor function in Parkinson’s trial, data show
- Caring for a friend gave me insight into the challenges of being a caregiver
- Later brain stimulation linked to faster decline in some with Parkinson’s
- Down the toilet went the Parkinson’s medicine, along with my patience
- Parkinson’s cognitive issues hit 1 in 3, highlighting screening need